In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
Join Precision and Akara Group for a special online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.
PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA
HOUSTON, TX – November 14, 2018 – Precision for Medicine and TRACON Pharmaceuticals (NASDAQ:TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell’s proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study, titled Detection of Endoglin-Expressing CTCs in Patients Enrolled in an Adaptive Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), is the first of its kind to show the detection and capture of CTCs from angiosarcoma cancer patients. Interim study results were presented at the Connective Tissue Oncology Society (CTOS) annual meeting in Rome, Italy. (more…)
On Wednesday, September 26th at 10:00am PDT/1:00pm EDT please join us for a special, live webinar:
Navigating the FDA’s Final Guidance on HCEI and PIE:
Value Communication That Works
Presented by:
New announced research finds Epiontis ID™ technology can advance newborn screening as well as treatment of HIV patients in low-resource countries. (more…)
TAPPING FORMER PAYER DECISION MAKERS BOYCE, HONCZ AND OYEKAN
BRINGS UNRIVALED INSIGHTS TO CLIENTS
APRIL 18th, 2018 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in demonstrating the value and outcomes of innovative medical products, today announced significant additions to its Payer Strategy Team with the hiring of former payer executives Marylou Buyse, Joe Honcz, and Elizabeth Oyekan. (more…)
Register today for our upcoming free live webinar Defend Your Value: Syncing Evidence and Access Strategies to Prepare for US Value Assessments on Wednesday, April 18, at 1:00 pm ET. (more…)
